Curated News
By: NewsRamp Editorial Staff
July 13, 2026

Onco-Innovations Achieves Key Milestone for ONC010 Candidate

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Onco-Innovations completed a reference standard for ONC010, strengthening its CMC framework and advancing toward clinical readiness.
  • The reference standard program for A83B4C63 ensures analytical testing, manufacturing consistency, and quality control for ONC010.
  • Onco-Innovations' progress with ONC010 brings us closer to new treatments for solid tumors, improving cancer care.
  • Dalton Pharma Services collaborated with Onco-Innovations to establish a qualified reference standard for its lead oncology drug.

Impact - Why it Matters

This milestone is important because it brings Onco-Innovations' lead oncology candidate, ONC010, closer to clinical trials. By establishing a qualified reference standard for the API, the company ensures manufacturing consistency and quality control, which are essential for regulatory approval. For investors and patients, this progress signals a potential new treatment option for solid tumors, addressing a significant unmet medical need in oncology.

Summary

Onco-Innovations Limited, a Canadian-based oncology company listed on the CBOE CA under the ticker ONCO and on the OTCQB as ONNVF, has announced a significant milestone in the development of its lead oncology candidate, ONC010. The company successfully completed its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient (API) supporting ONC010. This program was conducted in collaboration with Dalton Pharma Services and establishes a qualified reference standard to ensure consistency and quality in analytical testing, manufacturing, and future regulatory and clinical activities.

The completion of this reference standard program strengthens Onco-Innovations' chemistry, manufacturing, and controls (CMC) framework, which is crucial for advancing ONC010 toward clinical readiness. This milestone follows recent progress in API manufacturing, precursor scale-up, analytical method development, and chiral purity testing. The company continues its ongoing analytical development efforts, including stability testing, impurity profiling, formulation characterization, and quality control systems, all aimed at positioning ONC010 as a viable treatment for solid tumors.

Onco-Innovations holds an exclusive worldwide license to patented technology targeting solid tumors, and its mission is to pursue the prevention and treatment of cancer through pioneering research. For more details, the full press release is available at https://ibn.fm/EefIN. Investors can stay updated with the latest news on ONNVF at the company's newsroom https://ibn.fm/ONNVF. This announcement was disseminated by BioMedWire, a specialized communications platform focusing on biotechnology and life sciences, which is part of the Dynamic Brand Portfolio @ IBN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Achieves Key Milestone for ONC010 Candidate

blockchain registration record for this content.